The Manufacturers Life Insurance Company Purchases 7,728 Shares of The Cooper Companies, Inc. $COO

Key Points

• The Manufacturers Life Insurance Company increased its holdings in The Cooper Companies, Inc. to approximately $73.20 million, owning about 867,854 shares after purchasing an additional 7,728 shares.
• Analysts have mixed opinions on Cooper Companies, with Robert W. Baird lowering their price target to $85, while UBS Group upgraded it to a "buy" rating, reflecting diverse market sentiments on the stock.
• For Q4 2025, Cooper Companies expects earnings per share to be between 1.100 and 1.140, indicating optimism for future performance after reporting an EPS of $1.10 that exceeded expectations.

The Manufacturers Life Insurance Company grew its stake in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 0.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 867,854 shares of the medical device company's stock after buying an additional 7,728 shares during the quarter. The Manufacturers Life Insurance Company owned 0.43% of Cooper Companies worth $73,203,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Zions Bancorporation National Association UT acquired a new stake in Cooper Companies in the first quarter valued at $33,000. City Holding Co. acquired a new stake in Cooper Companies during the first quarter valued at approximately $34,000. GKV Capital Management Co. Inc. acquired a new stake in shares of Cooper Companies during the 1st quarter worth approximately $40,000. Larson Financial Group LLC increased its position in shares of Cooper Companies by 1,071.0% during the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company's stock valued at $61,000 after purchasing an additional 664 shares during the period. Finally, HM Payson & Co. grew its stake in Cooper Companies by 147.4% in the first quarter. HM Payson & Co. now owns 893 shares of the medical device company's stock valued at $75,000 after purchasing an additional 532 shares in the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Cooper Companies news, EVP Brian G. Andrews bought 1,525 shares of Cooper Companies stock in a transaction that occurred on Tuesday, September 2nd. The stock was acquired at an average cost of $65.68 per share, for a total transaction of $100,162.00. Following the completion of the transaction, the executive vice president directly owned 22,191 shares in the company, valued at $1,457,504.88. This represents a 7.38% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Daniel G. Mcbride purchased 3,000 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The stock was bought at an average price of $65.04 per share, for a total transaction of $195,120.00. Following the purchase, the chief operating officer directly owned 63,120 shares in the company, valued at $4,105,324.80. The trade was a 4.99% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.98% of the company's stock.

Cooper Companies Stock Performance

COO stock traded up $1.81 during mid-day trading on Wednesday, reaching $67.14. The company had a trading volume of 3,823,719 shares, compared to its average volume of 2,285,719. The stock's 50-day simple moving average is $72.13 and its two-hundred day simple moving average is $77.06. The stock has a market capitalization of $13.35 billion, a P/E ratio of 33.07, a P/E/G ratio of 1.63 and a beta of 0.97. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $112.38. The company has a quick ratio of 1.23, a current ratio of 2.12 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the prior year, the business earned $0.96 earnings per share. Cooper Companies's revenue for the quarter was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Research analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Analysts Set New Price Targets

COO has been the topic of several research analyst reports. Loop Capital set a $100.00 price objective on Cooper Companies in a research note on Tuesday, June 17th. BNP Paribas Exane upgraded shares of Cooper Companies from a "neutral" rating to an "outperform" rating and set a $92.00 price objective for the company in a research note on Tuesday, July 22nd. Wells Fargo & Company dropped their price objective on shares of Cooper Companies from $93.00 to $72.00 and set an "overweight" rating for the company in a report on Thursday, August 28th. UBS Group raised Cooper Companies to a "buy" rating in a research report on Tuesday, June 17th. Finally, Morgan Stanley set a $76.00 target price on Cooper Companies and gave the stock an "equal weight" rating in a research report on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Cooper Companies currently has a consensus rating of "Moderate Buy" and a consensus price target of $86.64.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.